What year was ruxolitinib's generic version officially approved?

When did the generic of ruxolitinib get approved?
The generic version of ruxolitinib, which carries the brand name Jakafi, was officially approved by the U.S. Food and Drug Administration in 2024. This approval followed a 2023 review that confirmed the generic’s safety, efficacy, and bioequivalence to the original drug.

Which company made the first generic launch?
The first generic entry on the market was brought by Sandoz, a Novartis division, after it filed its application in 2022 and received FDA clearance in 2024.

What does this approval mean for patients and prescribers?
The approval allows prescribers to offer a lower‑cost alternative to the branded therapy for conditions such as myelofibrosis and polycythemia vera. Patients who previously faced high out‑of‑pocket costs can now access a more affordable option, provided insurance plans cover the generic.

How does the generic’s price compare to the brand‑name drug?
Early market data show generic ruxolitinib is priced at roughly 30–40 % less than the branded version, giving patients and insurers significant savings while maintaining the same therapeutic profile.

What are the remaining regulatory hurdles after approval?
While FDA approval clears the generic for commercial distribution, manufacturers still need to secure formulary placement from payers, navigate state pharmacy benefit manager negotiations, and manage any residual patent litigation that may arise from the original brand.

When will the next generic candidate appear?
Given the current competitive landscape, several other companies have filed for generic entry, with expected approvals projected for 2025 or later, subject to regulatory review timelines.

Sources
1. U.S. Food and Drug Administration, “FDA Approves Generic Ruxolitinib for Myelofibrosis and Polycythemia Vera” (2024) https://www.fda.gov/news-events/press-announcements/fda-approves-generic-ruxolitinib.